Cancers, Vol. 16, Pages 1780: How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma
oss-Goupil
In the past decade, the therapeutic arsenal for metastatic bladder cancer has expanded considerably, with the development of immune checkpoint inhibitors (ICIs), antibody–drug conjugates such as enfortumab vedotin, and anti-fibroblast growth factor receptor agents. Clinical trials evaluating ICIs as neoadjuvants, adjuvants, or first- or second-line treatments have produced conflicting results. However, first-line therapeutic strategies have been redefined by the recent publication of results from two clinical trials: CheckMate-901, which demonstrated the superiority of combined treatment with n...
Source: Cancers - May 5, 2024 Category: Cancer & Oncology Authors: Mathieu Larroquette F élix Lefort Charlotte Domblides Luc H éraudet Gr égoire Robert Alain Ravaud Marine Gross-Goupil Tags: Review Source Type: research
Automatic detection method of bladder tumor cells based on color and shape features
In this study, based on microscopic hyperspectral data, an automatic detection algorithm of bladder tumor cells combining color features and shape features is proposed. Support vector machine (SVM) is used to build classification models and compare the classification performance of spectral feature, spectral and shape fusion feature, and the fusion feature proposed in this paper on the same classifier. The results show that the sensitivity, specificity, and accuracy of our classification algorithm based on shape and color fusion features are 0.952, 0.897, and 0.920, respectively, which are better than the classification al...
Source: Journal of Innovative Optical Health Sciences - May 4, 2024 Category: Biomedical Science Authors: Zitong Zhao Yanbo Wang Jiaqi Chen Mingjia Wang Shulong Feng Jin Yang Nan Song Jinyu Wang Ci Sun Source Type: research
A novel model of artificial intelligence based automated image analysis of CT urography to identify bladder cancer in patients investigated for macroscopic hematuria
CONCLUSIONS: We developed and tested an AI model for automatic image analysis of CTUs to detect UBC in patients with macroscopic hematuria. This model showed promising results with a high detection rate and excessive NPV. Further developments could lead to a decreased need for invasive investigations and prioritising patients with serious tumours.PMID:38698545 | DOI:10.2340/sju.v59.39930 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - May 3, 2024 Category: Urology & Nephrology Authors: Suleiman Abuhasanein Lars Edenbrandt Olof Enqvist Staffan Jahnson Henrik Leonhardt Elin Tr ägårdh Johannes Ul én Henrik Kj ölhede Source Type: research
Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancer tumors
Cancer Immunol Res. 2024 May 3. doi: 10.1158/2326-6066.CIR-23-1105. Online ahead of print.ABSTRACTGlutamine metabolism in tumor microenvironments critically regulates anti-tumor immunity. Using glutamine-antagonist prodrug JHU083, we report potent tumor growth inhibition in urologic tumors by JHU083-reprogrammed tumor-associated macrophages (TAMs) and tumor-infiltrating monocytes (TIMs). We show JHU083-mediated glutamine antagonism in tumor microenvironments induces TNF, pro-inflammatory, and mTORC1 signaling in intratumoral TAM clusters. JHU083-reprogrammed TAMs also exhibit increased tumor cell phagocytosis and diminishe...
Source: Cell Research - May 3, 2024 Category: Cytology Authors: Monali Praharaj Fan Shen Alex J Lee Liang Zhao Thomas R Nirschl Debebe Theodros Alok K Singh Xiaoxu Wang Kenneth M Adusei Kara A Lombardo Raekwon A Williams Laura A Sena Elizabeth A Thompson Ada Tam Srinivasan Yegnasubramanian Edward J Pearce Robert D Leo Source Type: research
A novel model of artificial intelligence based automated image analysis of CT urography to identify bladder cancer in patients investigated for macroscopic hematuria
CONCLUSIONS: We developed and tested an AI model for automatic image analysis of CTUs to detect UBC in patients with macroscopic hematuria. This model showed promising results with a high detection rate and excessive NPV. Further developments could lead to a decreased need for invasive investigations and prioritising patients with serious tumours.PMID:38698545 | DOI:10.2340/sju.v59.39930 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - May 3, 2024 Category: Urology & Nephrology Authors: Suleiman Abuhasanein Lars Edenbrandt Olof Enqvist Staffan Jahnson Henrik Leonhardt Elin Tr ägårdh Johannes Ul én Henrik Kj ölhede Source Type: research
The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer
Altern Ther Health Med. 2024 May 3:AT9333. Online ahead of print.ABSTRACTA patient with metastatic bladder cancer has had an ongoing 9-year complete remission on a clinical trial of immunotherapy with nivolumab and ipimumab, but he also was following an intensive dietary and nutritional supplement regimen. Whether this combination or the immunotherapy alone brought about his good outcome is unknown but could be clarified in future trials by improved data collection about dietary and supplement choices.PMID:38702166 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - May 3, 2024 Category: Complementary Medicine Authors: Linda L Isaacs Nicholas J Gonzalez Source Type: research
Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial
The objective of this phase II trial is to determine the effectiveness (in terms of biochemical, morphological and functional control), the safety and impact on quality of life, of prostate SABR with MRI guided focal dose intensification in males with intermediate and high-risk localized prostate cancer.METHODS: Patients with intermediate and high-risk prostate cancer according to NCCN definition will be treated with SABR 36.25 Gy in 5 fractions to the whole prostate gland with MRI guided simultaneous integrated focal boost (SIB) to the index lesion (IL) up to 50 Gy in 5 fractions, using a protocol of bladder trigone and u...
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Almudena Zapatero Pablo Castro Mar ía Roch Pablo Rodr íguez Carnero Sara Carroceda Alexandra Elena Stoica Rosciupchin Sergio Honorato Hern ández Leopoldo Cogorno Alfonso G ómez Iturriaga David B üchser García Source Type: research
Contemporary morbidity and mortality of open versus robotic cystectomy for bladder cancer: An analysis of the National Surgical Quality Improvement Program (NSQIP) procedure targeted cystectomy database
CONCLUSIONS: RARC was associated with reduced risk of multiple 30-day complications, including mortality, as well as organ system and cystectomy-specific outcomes. These data support the clinical benefit of increased adoption of RARC.PMID:38702232 | DOI:10.1016/j.urolonc.2024.03.017 (Source: Urologic Oncology)
Source: Urologic Oncology - May 3, 2024 Category: Urology & Nephrology Authors: Zachary Melchiode Siqi Hu Jiaqiong Xu Carlos Riveros Sameer Farooq Sanjana Ranganathan Emily Huang Brian J Miles Dharam Kaushik Christopher J D Wallis Raj Satkunasivam Source Type: research
A novel model of artificial intelligence based automated image analysis of CT urography to identify bladder cancer in patients investigated for macroscopic hematuria
CONCLUSIONS: We developed and tested an AI model for automatic image analysis of CTUs to detect UBC in patients with macroscopic hematuria. This model showed promising results with a high detection rate and excessive NPV. Further developments could lead to a decreased need for invasive investigations and prioritising patients with serious tumours.PMID:38698545 | DOI:10.2340/sju.v59.39930 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - May 3, 2024 Category: Urology & Nephrology Authors: Suleiman Abuhasanein Lars Edenbrandt Olof Enqvist Staffan Jahnson Henrik Leonhardt Elin Tr ägårdh Johannes Ul én Henrik Kj ölhede Source Type: research
The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer
Altern Ther Health Med. 2024 May 3:AT9333. Online ahead of print.ABSTRACTA patient with metastatic bladder cancer has had an ongoing 9-year complete remission on a clinical trial of immunotherapy with nivolumab and ipimumab, but he also was following an intensive dietary and nutritional supplement regimen. Whether this combination or the immunotherapy alone brought about his good outcome is unknown but could be clarified in future trials by improved data collection about dietary and supplement choices.PMID:38702166 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - May 3, 2024 Category: Complementary Medicine Authors: Linda L Isaacs Nicholas J Gonzalez Source Type: research
A novel model of artificial intelligence based automated image analysis of CT urography to identify bladder cancer in patients investigated for macroscopic hematuria
CONCLUSIONS: We developed and tested an AI model for automatic image analysis of CTUs to detect UBC in patients with macroscopic hematuria. This model showed promising results with a high detection rate and excessive NPV. Further developments could lead to a decreased need for invasive investigations and prioritising patients with serious tumours.PMID:38698545 | DOI:10.2340/sju.v59.39930 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - May 3, 2024 Category: Urology & Nephrology Authors: Suleiman Abuhasanein Lars Edenbrandt Olof Enqvist Staffan Jahnson Henrik Leonhardt Elin Tr ägårdh Johannes Ul én Henrik Kj ölhede Source Type: research
The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer
Altern Ther Health Med. 2024 May 3:AT9333. Online ahead of print.ABSTRACTA patient with metastatic bladder cancer has had an ongoing 9-year complete remission on a clinical trial of immunotherapy with nivolumab and ipimumab, but he also was following an intensive dietary and nutritional supplement regimen. Whether this combination or the immunotherapy alone brought about his good outcome is unknown but could be clarified in future trials by improved data collection about dietary and supplement choices.PMID:38702166 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - May 3, 2024 Category: Complementary Medicine Authors: Linda L Isaacs Nicholas J Gonzalez Source Type: research
A novel model of artificial intelligence based automated image analysis of CT urography to identify bladder cancer in patients investigated for macroscopic hematuria
CONCLUSIONS: We developed and tested an AI model for automatic image analysis of CTUs to detect UBC in patients with macroscopic hematuria. This model showed promising results with a high detection rate and excessive NPV. Further developments could lead to a decreased need for invasive investigations and prioritising patients with serious tumours.PMID:38698545 | DOI:10.2340/sju.v59.39930 (Source: Scandinavian Journal of Urology)
Source: Scandinavian Journal of Urology - May 3, 2024 Category: Urology & Nephrology Authors: Suleiman Abuhasanein Lars Edenbrandt Olof Enqvist Staffan Jahnson Henrik Leonhardt Elin Tr ägårdh Johannes Ul én Henrik Kj ölhede Source Type: research
The Missing Trial Variable: A Case Report on Dietary Modification in a Patient with Durable Complete Remission After an Immunotherapy Clinical Trial for Metastatic Bladder Cancer
Altern Ther Health Med. 2024 May 3:AT9333. Online ahead of print.ABSTRACTA patient with metastatic bladder cancer has had an ongoing 9-year complete remission on a clinical trial of immunotherapy with nivolumab and ipimumab, but he also was following an intensive dietary and nutritional supplement regimen. Whether this combination or the immunotherapy alone brought about his good outcome is unknown but could be clarified in future trials by improved data collection about dietary and supplement choices.PMID:38702166 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - May 3, 2024 Category: Complementary Medicine Authors: Linda L Isaacs Nicholas J Gonzalez Source Type: research
